In fact, since 2016, non-small cell lung cancer (NSCLC) patients who are unable to provide tumor specimens can be tested for EGFR mutations in plasma, using the U.S. Food and Drug Administration (FDA)-approved cobas EGFR Mutation Test v2 [80]. Here, EGFR is linked to non-small cell lung carcinoma.